Protara Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview

Protara Therapeutics

30/04/2024 15:38

* Protara Therapeutics Inc  TARA.OQ   TARA.O  is expected
to show
no change in quarterly revenue when it reports  results on May 2
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Protara Therapeutics Inc
is
for a loss of 92 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Protara
Therapeutics Inc is $23.00​, above​ its last closing price
of $3.10. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023              -0.92      -0.90     Beat    1.9
 Sep. 30 2023              -0.98      -0.87     Beat    11.2
 Jun. 30 2023  -0.88       -0.87      -1.00     Missed  -14.3​
 Jan. 1 0001   -0.91       -0.88      -0.80     Beat    8.8
 ​​Dec.                    -0.75      -1.55     Missed  -106.7
 31 2022                                                
 Sep. 30 2022  -1.02       -0.76      -0.68     Beat    10.1​
 Jan. 1 0001   -1.02       -0.94      -0.80     Beat    14.6
 Mar. 31 2022  -1.01       -0.90      -0.96     Missed  -6.3
 This summary was machine generated April 30 at 14:38 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)